InMed Pharmaceuticals (INM) Set to Release Quarterly Earnings on Thursday

by · The Cerbat Gem

InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) is projected to post its Q1 2027 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($94.4436) per share and revenue of $0.30 million for the quarter. Investors may review the information on the company’s upcoming Q1 2027 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 7:00 AM ET.

InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) last posted its quarterly earnings data on Wednesday, September 9th. The company reported ($1.24) earnings per share (EPS) for the quarter.

InMed Pharmaceuticals Price Performance

INM stock opened at $1.63 on Tuesday. InMed Pharmaceuticals has a 52-week low of $0.57 and a 52-week high of $2.33. The company’s 50 day simple moving average is $1.38 and its 200-day simple moving average is $1.21. The firm has a market capitalization of $5.40 million, a P/E ratio of -0.99 and a beta of 0.93.

InMed Pharmaceuticals shares are set to split before the market opens on Thursday, November 5th. The 2-1 split was recently announced. The newly issued shares will be issued to shareholders after the market closes on Wednesday, November 4th.

Insider Buying and Selling at InMed Pharmaceuticals

In related news, major shareholder Adar1 Capital Management, Llc purchased 54,256 shares of InMed Pharmaceuticals stock in a transaction dated Tuesday, September 15th. The stock was acquired at an average cost of $1.30 per share, with a total value of $70,532.80. Following the completion of the transaction, the insider directly owned 883,761 shares of the company’s stock, valued at $1,148,889.30. This trade represents a 6.54% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders bought 155,584 shares of company stock valued at $203,804. 0.85% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of InMed Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 9th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the company presently has a consensus rating of “Sell”.

Check Out Our Latest Analysis on INM

About InMed Pharmaceuticals

(Get Free Report)

InMed Pharmaceuticals Inc is a Canada-based biotechnology company focused on developing pharmaceutical therapies that target the endocannabinoid system. The company’s research uses rare cannabinoids and cannabinoid analogs to address diseases with significant unmet medical needs, with an emphasis on neurological, ophthalmic and dermatological conditions.

InMed’s pipeline has included INM-901, an investigational program being developed for Alzheimer’s disease, as well as earlier programs targeting eye diseases such as glaucoma and age-related macular degeneration and the rare skin disorder epidermolysis bullosa.

Recommended Stories